title: Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases.
abstract: Mitotic activity and tumor size are currently regarded as the most powerful prognostic indicators for patients with gastrointestinal stromal tumor (GIST). This retrospective study evaluated the prognostic accuracy of MIB-1 proliferative index (PI) in combination with these two indicators in 35 GIST patients. Within a high-risk group, determined initially by tumor size and mitotic count, overall survival was significantly shorter for patients whose tumors had PI > or = 10% MIB-1 positive cells. When tumor location (gastric versus small intestine) was taken into account, a combination of tumor size, mitotic count, and PI > or = 10% identified a subgroup of patients with significantly shorter survival for gastric (but not small intestinal) GIST. Based on our results, MIB-1 immunostaining, when used in combination with tumor size and mitotic count, appears to be a powerful tool for identifying patients, especially those with gastric tumors, at high risk of recurrence and early tumor-related death.
authors.affiliation: Department of Pathology, University Hospital of Nantes, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Toquet
authors.forename: Jean Claude
authors.initials: JC
authors.lastname: Le Néel
authors.forename: Louis
authors.initials: L
authors.lastname: Guillou
authors.forename: Karine
authors.initials: K
authors.lastname: Renaudin
authors.forename: Antoine
authors.initials: A
authors.lastname: Hamy
authors.forename: Marie-Françoise
authors.initials: MF
authors.lastname: Heymann
authors.forename: Sophie
authors.initials: S
authors.lastname: Simon-Valla
authors.forename: Joël
authors.initials: J
authors.lastname: Le Borgne
authors.forename: Christine
authors.initials: C
authors.lastname: Maugard
authors.forename: Maryse
authors.initials: M
authors.lastname: Fiche
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000401:mortality / Q000473:pathology*; D007422:Intestines / Q000473:pathology; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D008940:Mitotic Index; D009130:Muscle, Smooth / Q000473:pathology; D009217:Myosarcoma / Q000401:mortality / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology*; D017154:Stromal Cells / Q000473:pathology*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen